Key takeaways
- The 2026 and 2027 Lists name “mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)” in S4.4.1, metabolic modulators, prohibited at all times.
- WADA added MOTS-c as an example in the 2025 List; UK Anti-Doping said that year’s new examples were “additional examples of substances that are already prohibited”.
- Because S4 addresses it, MOTS-c is not an S0 substance: substances in S4.4 are non-Specified, while everything in S0 is Specified.
- Under the 2021 Code, presence or use of a non-Specified Substance carries four years unless the athlete establishes the violation was not intentional; the 2027 Code keeps four years as the starting point.
- USADA and Sport Integrity Australia both say a therapeutic use exemption is unlikely.
01What does the WADA Prohibited List say about MOTS-c?
The Prohibited List is a mandatory International Standard under the World Anti-Doping Code, revised every year. MOTS-c sits in class S4, hormone and metabolic modulators.
The 2026 List, in force since 1 January 2026, heads S4 “PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)” and says: “Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances.” Under S4.4, metabolic modulators, entry S4.4.1 covers “Activators of the AMP-activated protein kinase (AMPK), e.g. … (BAM15), AICAR, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)”. AMPK is an enzyme that senses a cell’s energy state. The same entry lists PPARδ agonists such as GW1516 and Rev-erbα agonists such as SR9009.
Why not S0? Class S0, non-approved substances, covers “any pharmacological substance which is not addressed by any of the subsequent sections of the List” and has no current approval for human therapeutic use. MOTS-c is addressed by S4, so S4’s rules apply to it. The difference matters. Everything in S0 is a Specified Substance; substances in S4.4 are not.
| List | In force | MOTS-c | S4.4.1 wording |
|---|---|---|---|
| 2024 | 1 Jan 2024 | Not named | Activators of AMPK, “e.g. AICAR”, with PPARδ and Rev-erbα agonists |
| 2025 | 1 Jan 2025 | Named; WADA: “added as an example” | AMPK activators, e.g. AICAR, MOTS-c |
| 2026 | 1 Jan 2026 | Named | AMPK activators, e.g. BAM15, AICAR, MOTS-c |
| 2027 | 1 Jan 2027 | Named | Same AMPK entry; seladelpar and SLU-PP-332 and SLU-PP-915 added elsewhere in S4.4.1 |
02When was MOTS-c added, and was it prohibited before?
WADA’s Executive Committee approved the 2025 List on 12 September 2024. WADA published it on 25 September 2024, and it took effect on 1 January 2025. WADA’s explanatory note for that List says: “Mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) was added as an example of an AMP-activated protein kinase activator.”
Naming it did not create the prohibition, by UK Anti-Doping’s account. Its summary of the 2025 List gave MOTS-c among the year’s new examples and said: “Please note that these are not new substances being added to the 2025 List for the first time but are additional examples of substances that are already prohibited.” FDA staff’s 2026 briefing adds that the Global Drug Reference Online database (Global DRO) listed MOTS-c as a prohibited substance when FDA consulted it on 20 March 2024, drawing on the 2024 List’s hormone and metabolic modulators class.
| Date | What happened |
|---|---|
| 2019 | The anti-doping laboratory at the German Sport University Cologne publishes a mass-spectrometry method for MOTS-c in plasma “for doping control purposes”, validated to WADA’s laboratory standard (Knoop, Rapid Communications in Mass Spectrometry). |
| 20 Mar 2024 | FDA staff consult Global DRO, which lists MOTS-c as prohibited, drawing on the 2024 List’s hormone and metabolic modulators class (the access date in FDA’s 2026 briefing). |
| 12 Sep 2024 | WADA’s Executive Committee approves the 2025 List. |
| 25 Sep 2024 | WADA publishes the 2025 List, with MOTS-c named in S4.4.1. |
| 1 Jan 2025 | The 2025 List takes effect. |
| 1 Jan 2026 | The 2026 List takes effect, MOTS-c still named. |
| 1 Jan 2027 | The 2027 List and the 2027 World Anti-Doping Code take effect. |
03What follows for a non-Specified Substance under the Code?
The List decides what is prohibited. The World Anti-Doping Code decides what counts as a violation and what follows. These are the 2021 Code’s articles, which apply until the 2027 Code takes effect on 1 January 2027.
It is each athlete’s “personal duty to ensure that no Prohibited Substance enters their bodies”, and “it is not necessary that intent, Fault, Negligence or knowing Use on the Athlete’s part be demonstrated”.
A violation does not need a positive test. “The success or failure of the Use or Attempted Use of a Prohibited Substance or Prohibited Method is not material.”
Possession of a substance prohibited out of competition is a violation unless the athlete establishes that it is consistent with a therapeutic use exemption “or other acceptable justification”.
For a non-Specified Substance, the period of ineligibility is four years unless the athlete “can establish that the anti-doping rule violation was not intentional” (Article 10.2.1.1). Otherwise it is two years (Article 10.2.2), subject to the Code’s reductions.
Substances in S0 are Specified, a different footing: for them the default is two years unless the anti-doping organisation establishes intent.
From 1 January 2027. The 2027 Code keeps four years as the starting point for presence or use of a non-Specified Substance and sets out when it may be reduced (Article 10.2.1). Possession has its own scale (Article 10.2.5).
04Can an athlete get a therapeutic use exemption for MOTS-c?
The anti-doping bodies we read say it is unlikely. USADA: “It is highly unlikely an athlete would get a TUE approved for MOTS-c because there is no approved therapeutic use for this experimental drug.” Sport Integrity Australia, on unapproved peptides in general: “A TUE is unlikely to be granted for an unregistered medicine”. MOTS-c has no FDA approval, and FDA staff found no MOTS-c product authorised by the European Medicines Agency: is MOTS-c legal in the US?
| Country | Body | What it has said about MOTS-c |
|---|---|---|
| United Kingdom | UK Anti-Doping | Among the 2025 List’s new examples, which it called “additional examples of substances that are already prohibited”. |
| Australia | Sport Integrity Australia | “Many unapproved peptides are prohibited in sport”; MOTS-C is among its “common examples”. Possession or use can lead to an anti-doping rule violation and a ban. |
| United States | USADA | “prohibited at all times under Section 4.4 Metabolic Modulators, 4.4.1”; “explicitly listed”. Athletes should be “extremely wary” of experimental peptides sold with “for research purposes only” labels. |
National medicines law does not move the sports listing. The US HHS compounding policy of October 2026, which names MOTS-c, concerns licensed US compounders, not anti-doping rules. Australia and the UK: is MOTS-c legal in Australia? and is MOTS-c legal in the UK?
05What changes in 2027?
WADA’s 2027 List, in force from 1 January 2027, keeps MOTS-c in S4.4.1. Its explanatory note records new S4 examples: seladelpar as a PPAR-delta agonist, and SLU-PP-332 and SLU-PP-915 as metabolic modulators. It also adds “peptides” to the S0 examples, noting that many unapproved peptides “fall under the S0 (Non-Approved Substances) class, or other classes (such as S2 or S4)”. It adds: “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.”
For MOTS-c nothing changes on the List: it was named before and is named still. The 2027 Code, effective the same day, restructures how sanction lengths are set (above). How the List treats other research peptides: peptides and anti-doping.
06What we don’t know
How many cases have involved MOTS-c. We have not counted anti-doping cases by substance.
Why WADA named it in 2025. The explanatory note records the addition but does not set out the evidence behind it.
The 2027 Code in full. We read the articles cited here, not the whole Code.
The research on MOTS-c is in our MOTS-c research guide and our MOTS-c research overview. Changes are logged in our regulatory changelog.
This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice, and athletes should check with their national anti-doping organisation.